The correlation between crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer | Zendy

Tangfeng Lv | Zendy; Qian Zou | Zendy; Zhengbo Song | Zendy; Hongbing Liu | Zendy; Qiming Wang | Zendy; Yong Song | Zendy

Open Access

The correlation between crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer

Author(s) -

Tangfeng Lv,

Qian Zou,

Zhengbo Song,

Hongbing Liu,

Qiming Wang,

Yong Song

Publication year - 2018

Publication title -

journal of thoracic disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.682

H-Index - 60

eISSN - 2077-6624

pISSN - 2072-1439

DOI - 10.21037/jtd.2018.05.55

Subject(s) - crizotinib , lung cancer , medicine , oncology , clinical significance , dna sequencing , computational biology , bioinformatics , cancer research , genetics , biology , gene , malignant pleural effusion

Non-small cell lung cancer (NSCLC) patients with EML4-ALK fusion exhibited various durations of response to crizotinib. Molecular heterogeneity is also one of the factors associated with resistance to crizotinib. This study investigated the relevance of molecular heterogeneity to the clinical efficacy of crizotinib using next-generation sequencing (NGS).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research